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BACKGROUND For the treatment of chronic total occlusion (CTO), the
efﬁcacy and safety of the bioresorbable vascular scaffold is still
considered limited. The aim of this study was to assess the feasibility
of BVS for the CTO percutaneous treatment, analyze clinical outcomes
and intracoronary imaging at one year follow-up. The reabsorption of
the BVS could provide some advantages at long-term follow-up as
compared with metallic drug-eluting stents.
METHODS Between October 2013 and January 2015, percutaneous
treatment of CTO with BVS implantation were performed in 66 pa-
tients (66 lesions). The mean patient age was 6211 years and 63%
patients were male, 45.1% suffered from hypertension and 30.3% from
diabetes. The decision of an antegrade or retrograde approach was
taken by the operator after a thorough study of the CTO anatomy. An
antegrade approach was the strategy used to cross 42% CTO, 33% a
retrograde approach, while in 25% antegrade and dissection technique
was needed. The most frequently treated vessel was the LAD (45%).
Estimate the size of the BVS was made on the basis of the IVUS ex-
amination just after ﬁrst balloon predilatation. The total scaffold
length implanted per lesion was 55.818.9 mm. Post-dilatation was
undertaken in 93%. All scaffolds were successfully delivered and
deployed. Optical coherence tomography (OCT) was performed after
BVS implantation. Primary endpoints were procedural success of
deployment of the BVS at the target lesion and absence of in-hospital
major adverse events (death, Q-wave myocardial infarction, stroke or
any repeat target lesion revascularization). After 6 month of BVS im-
plantation clinical evaluation was made, all included patients will
have control angiography with OCT in 12 months follow-up.
RESULTS All scaffolds were delivered and deployed successfully. The
ﬁnal OCT analysis not revealed any signiﬁcant scaffold malapposition.
9.1% patients presented signiﬁcant troponin elevations in the range
associatedwith a non-Q periproceduralmyocardial infarction. No other
in-hospital adverse clinical events were recorded. After 121 months of
follow-up, the events rate was 6.0% due to 4 repeat revascularization (3
PCI and 1 CABG). Re-evaluation by angiography with OCT will be ob-
tained in next 12 months follow-up after procedure.
CONCLUSIONS In this study we demonstrated midterm safety and
efﬁcacy BVS implantation in percutaneous treatment of chronic total
occlusion.
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BACKGROUND In the Absorb II study the use of the scaffold was
associated with similar results compared with the everolimus eluting
stent. Lesion complexity in Absorb II as well as follow-up (12 months)
was limited. We evaluated clinical results in our prospective registry
including a real world population with dual antiplatelet therapy for 6
months (stable angina) or 12 months (acute coronary syndrome).
METHODS In this prospective registry (clinicaltrials.gov
NCT01583608) 236 patients were enrolled and treated with the bio-
resorbable scaffold (Absorb). Patients had stable or unstable coronary
artery disease. Pre-dilation was mandatory and post-dilation with a
high-pressure balloon was performed in patients with a scaffold
length >12mm. Quantitative coronary angiography pre and post
scaffold implantation was done. Patients received dual antiplatelet
therapy for 6 months (aspirin and clopidogrel) for stable angina pec-
toris and 12 months for acute coronary syndrome. Mean follow-up was
382 days. Primary outcome measure was a device oriented composite
endpoint deﬁned as cardiac death, myocardial infarction not clearly
related to a non-target vessel and target lesion revascularization.
Scaffold thrombosis were deﬁned according to the ARC criteria.RESULTS Patients suffered from an acute coronary syndrome in 44%,
diabetes mellitus in 24%. Multiple scaffold implantations were per-
formed in 24% (N¼61/74 lesions) with a mean 2.20.5 scaffolds (range
2-4), resulting in a total mean scaffold length of 48mm (range 28-
112mm). Minimal lumen diameter (MLD) pre PCI was 1.040.50mm in
the single scaffold and 0.890.49 in the multiple scaffold group.
Lesion length was 13.55.7mm in the single versus 30.015.5mm in
the multiple scaffold group. Reference diameter and MLD in the
scaffold and total segment were signiﬁcantly smaller with multiple
compared with single scaffold treatment. Mean length of scaffold
segment was 20mm (8-28mm) with a single scaffold and 37mm
ranging from 20 to 112mm with multiple scaffolds. Pre-dilatation was
performed in all cases. Acute gain in the scaffold segment was
1.370.47mm, leading to a ﬁnal minimal luminal diameter of
2.440.41mm in the single scaffold and 2.270.37mm in the multiple
scaffold group. Reference diameter post PCI was 2.940.77mm in the
single and 2.770.38mm in the multiple scaffold group. With our dual
antiplatelet strategy there was no deﬁnite scaffold thrombosis. Within
12 months follow-up the device oriented composite endpoint was low
with 2.2% (0.8% in the single versus 6.8% in the multiple scaffold
group, p¼0.003).
CONCLUSIONS With careful predilation and post dilation using high
pressure balloons in long scaffold segments and dual antiplatelet
therapy there was no scaffold thrombosis. Device oriented composite
endpoint was low with a signiﬁcantly higher rate with multiple scaf-
fold implantation. Diabetes mellitus and length of scaffold segment
were signiﬁcant predictors for the occurrence of a device oriented
endpoint.
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BACKGROUND The fate of side branch (SB) ostia jailed by struts of the
Absorb bioresorbable vascular scaffold (BVS, Abbott Vascular, Santa
Clara, CA) has not yet been fully explored.
METHODS We performed a 3D-OCT sub-analysis of the ABSORB
Cohort B trial. In this trial, 101 patients were included, all treated with
a 3.0x18mm BVS. According to study protocol, the ﬁrst 45 patients
(cohort B1; CB1) underwent repeat angiography with invasive imaging
(IVUS; OCT was optional) at 6 months and 2 years; the other 56 pa-
tients (cohort B2; CB2) were examined at 1 and 3 years. According to
an additional protocol amendment all patients were consented again
to return for another repeat angiography at 5 years. We present 3D-
OCT assessments of jailed SB ostia from patient with true serial
follow-up from baseline to 5 years, using the validated ‘cut-plane’;
analysis method of the new QAngioOCT 1.0 software (Medis Specials
BV, Leiden, the Netherlands).
RESULTS A total of 27 patients (11 in CB1, 16 in CB2) with 100 jailed SB
ostia (41 in CB1, 49 in CB2) were evaluated. A total of 12 jailed SB ostia
could be truly serially assessed (3 from CB1, 9 from CB2). In CB1, the
mean post-procedural ostial surface was 2.750.2.96mm2, which
decreased to 1.981.85mm2 at 6 months, decreased a bit further to
1.240.66mm2 at 2 years, but increased to 2.830.82mm2 at 5 years
(p-values not calculated due to low number of cases). In Cohort B2,
the mean post-procedural ostial surface was 0.730.87mm2, which
decreased to 0.490.32mm2 at 1 year (p¼0.30), remained stable
(0.440.24mm2) at 3 years (p¼0.45), but signiﬁcantly increased to
0.800.48mm2 at 5 years (p¼0.008). The total number of compart-
ments per jailed ostium decreased from baseline to 2 years (CB1) and 3
years (CB2), and remained similar from 2/3 years to 5 years (see
ﬁgure).
